AQR Capital Management LLC Sells 291,259 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

AQR Capital Management LLC decreased its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 36.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 502,375 shares of the company’s stock after selling 291,259 shares during the quarter. AQR Capital Management LLC owned approximately 0.92% of Voyager Therapeutics worth $3,974,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of VYGR. Ameritas Investment Partners Inc. boosted its holdings in shares of Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after buying an additional 1,300 shares during the period. Plato Investment Management Ltd acquired a new position in shares of Voyager Therapeutics in the first quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Voyager Therapeutics by 104.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 10,404 shares of the company’s stock worth $97,000 after purchasing an additional 5,311 shares during the period. SG Americas Securities LLC acquired a new stake in Voyager Therapeutics during the 2nd quarter worth approximately $85,000. Finally, ProShare Advisors LLC bought a new stake in Voyager Therapeutics in the 1st quarter valued at $101,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VYGR. Wedbush dropped their target price on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, August 20th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.83.

Voyager Therapeutics Stock Up 17.5 %

VYGR stock opened at $7.04 on Friday. The company’s 50-day moving average price is $6.72 and its two-hundred day moving average price is $7.87. The firm has a market cap of $382.93 million, a P/E ratio of -140.80 and a beta of 0.91. Voyager Therapeutics, Inc. has a 12 month low of $5.71 and a 12 month high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. The business had revenue of $29.58 million for the quarter, compared to analysts’ expectations of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same period last year, the firm posted ($0.51) earnings per share. Equities analysts predict that Voyager Therapeutics, Inc. will post -1.44 EPS for the current year.

Insider Buying and Selling

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the transaction, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.53% of the stock is owned by corporate insiders.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.